Bli medlem
Bli medlem

Du är här


Aspera, Inc.: Bluebee Teams Up With Aspera for Fast Transfer of Genomics Data for Clinical Applications

Provider of High Performance Genome Analytics Platform Deploys Aspera On IBM
Cloud to Exchange Data With Hospitals, Diagnostic Test Providers, Research
Centers and Other Clients

ARMONK, N.Y., April 05, 2016 (GLOBE NEWSWIRE) -- IBM (NYSE:IBM) today
announced that Bluebee, a leading provider of high-performance genomics
solutions, has deployed high-speed file transfer solutions from Aspera, an
IBM company, running on the IBM Cloud and integrated directly into the
Bluebee genome analytics platform. Aspera transfers reduce the end-to-end
turnaround time of computational data analysis, enabling Bluebee to deliver
results to clients significantly faster and more efficiently than was
previously possible.

Bluebee's genome analytics platform enables efficient pipeline processing by
combining best-in-class tools with a high-performance computational engine.
The addition of Aspera's flexible and highly scalable Aspera On Demand (AOD)
software supports Bluebee's users with high-speed, reliable and resilient
transfers even for the largest data sets, including entire genomes that can
reach up to 90 GB per sample.

Bluebee's clients submit samples of all sizes, the largest coming from cancer
centers, which typically submit 2-3 tumor cell samples along with a control
sample for each patient, bringing the total volume of NGS data to upwards of
360 GB per patient that must be uploaded to the platform.

Initial tests comparing FTPS and Aspera found that transfer speeds for a 10GB
file sent over the same network have increased by a factor of 6 with Aspera.

Tumor and other samples are collected, are prepped and sequenced in a Wet Lab,
and the resulting data is then transferred to Bluebee's Silicon Lab for
secondary analysis. Whole genomes, cancer sequencing data, agricultural data
and other large files are transferred while sequencing is ongoing to save
time, while smaller samples are uploaded in batches once sequencing is

The fusion of technologies pairing Bluebee's advanced genome analytics
application and Aspera FASP® high-speed transfer technology supports fast,
efficient and affordable diagnosis, providing significant implications for
clinical settings. By enabling hospitals, diagnostic test providers, research
centers and other clients to quickly and securely transfer large volumes of
genomics data, Aspera shortens the data analysis turnaround time so data can
be interpreted and patients can be diagnosed and begin therapy as soon as

AOD's pay-as-you-go model offering fits with Bluebee's usage-based billing to
eliminate the burden of time and capital expenditure that is incurred to
manage and maintain in-house infrastructure.

"When on-site infrastructure is not able to scale up with increasing mass data
volumes, sequence waiting lists are inevitably formed. This seriously hampers
the speed of diagnosis and delays research. Bluebee addresses this genome
analysis challenge by providing a highly scalable private cloud platform for
accelerated processing of mass volumes of NGS data, and the speed and
resiliency of the Aspera solution allows our clients to transfer huge data
sets directly to the platform," said Kurt Florus, CTO at Bluebee. "Together
the solutions significantly accelerate the turnaround time for data
processing while at the same time solving the data throughput issue. We
strongly believe in the value Aspera brings to our customers and in the
competitive advantage the collaboration gives us."

"In the field of genomic analysis, platforms like Bluebee can make computing,
processing and analysis as fast as imaginable, but the reality is the impact
is lost if the data takes forever to transfer. Shortening the time it takes
to transfer huge data volumes between labs, analysis platforms and the
hospitals that rely on this data for diagnosis will have a tremendous impact
on clinics' ability to treat patients in a timely manner," said Richard
Heitmann, vice president of marketing at Aspera.

Aspera CEO&co-founder Michelle Munson will co-present alongside Bluebee CEO
Hans Cobben: "How Bluebee&Others Solve the File Exchange Problem for
Bioinformatics," on Wednesday, April 6 at 2:55pm at Bio-IT World. Visit
Aspera at Booth #261.

About Aspera
Aspera, an IBM company, is the creator of next-generation transport
technologies that move the world's data at maximum speed regardless of file
size, transfer distance and network conditions. Part of IBM Cloud, Aspera
software is powered by the Emmy® award-winning FASP® protocol to deliver the
fastest, most predictable file-transfer, share and sync experience across
on-premises, cloud, and hybrid infrastructure. Aspera's core technology
delivers unprecedented control over bandwidth, complete security and
uncompromising reliability. Organizations across a variety of industries on
six continents rely on Aspera software for the business-critical transport of
their digital assets. Please visit and follow us on
Twitter@asperasoft for more information.

About Bluebee
Bluebee provides high performance genomics solutions, enabling genomic labs to
substantially reduce cost and time-to-diagnosis. Bluebee's unique cloud-based
accelerated genomics platform enables fast, efficient and affordable
processing of large volumes of genomics data. With Bluebee's private-cloud
based solutions, labs can run their pipelines orders of magnitude faster
without compromising the algorithms and methods used, nor the flexibility
required to provide quality, sensitivity and reliability. Please visit and follow us on Twitter @bluebeegenomics for more
Media contacts:

Americas/Asia: Kim Willsher, +1 (310) 569 2603
Europe: Louise Wells, +44 (0) 20 7403 8878
Red Lorry Yellow Lorry - Aspera's PR agency


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aspera, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.